User:Mr. Ibrahem/Umeclidinium

Umeclidinium, sold under the trade name Incruse Ellipta, is a medication used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not used for asthma. It is used by breathing the medication into the lungs.

Side effects may include change in taste, cough, and eye pain. Severe side effects may include anaphylaxis, bronchospasm, urinary retention, and glaucoma. It is not recommended in those with severe milk protein allergies. It is a long-acting muscarinic antagonist (LAMA).

Umeclidinium was approved for medical use in the United States in 2014. It is on the World Health Organization's List of Essential Medicines as an alternative to tiotropium. In the United Kingdom a month of medication costs the NHS about £28 while in the United States this amount is about 380 USD. It is also available in combination as umeclidinium/vilanterol and fluticasone/umeclidinium/vilanterol.